#RNA targeted drug discovery summit

[mysticalpeacenut]

What’s New with Depixus? Recent Press Coverage

In the rapidly advancing world of biotechnology and drug discovery, keeping up with the latest developments is crucial for stakeholders, investors, and the scientific community. Depixus, a trailblazer in RNA targeting technology, has been making headlines recently, with significant accomplishments and milestones that underscore its commitment to innovation. This blog will explore the latest press coverage, including the recent Press Release Depixus, participation in the RNA Targeted Drug Discovery Summit, and recognition at the Ignite Award ceremony.

1. Spotlight on Recent Achievements

Depixus has garnered considerable attention in the media for its groundbreaking work in the field of RNA-targeted drug discovery. The company’s pioneering approach aims to harness the power of RNA to develop innovative therapeutics that can target diseases at a molecular level. This novel strategy is particularly significant in the fight against complex diseases, including cancer and genetic disorders, where traditional treatment modalities often fall short.

In a recent Press Release, Depixus announced exciting advancements in its research and development initiatives, highlighting their latest findings and ongoing projects. These developments have not only captured the interest of industry experts but have also been featured in various scientific publications and news outlets, emphasizing the company's role as a leader in RNA-based therapeutics.

2. Participation in the RNA Targeted Drug Discovery Summit

Another significant aspect of Depixus' recent press coverage is its active participation in the RNA Targeted Drug Discovery Summit. This prestigious event brought together thought leaders, researchers, and pharmaceutical professionals to discuss the latest trends, challenges, and opportunities in RNA-targeted therapies.

During the summit, Depixus showcased its innovative technologies and methodologies, gaining insights into how RNA can be leveraged to develop more effective drugs. The discussions revolved around various applications of RNA technology, including the potential for targeting specific RNA molecules to treat diseases that have historically been difficult to manage. Presenters from Depixus shared compelling data from their ongoing studies, illustrating how their approach could revolutionize the development of targeted therapies.

The visibility gained at this summit not only enhances Depixus' reputation within the scientific community but also reinforces its commitment to advancing RNA-based drug discovery. Attendees left the event with a deeper understanding of the transformative potential that Depixus brings to the table, further solidifying the company’s position as a key player in the industry.

3. Recognition at the Ignite Award Ceremony

As a testament to its outstanding contributions to the field, Depixus was recently honored with the Ignite Award. This accolade recognizes organizations and individuals who have made significant strides in advancing innovative solutions in biotechnology. The award ceremony brought together industry leaders and innovators, celebrating the groundbreaking work being done across the sector.

Winning the Ignite Award is not only a significant achievement for Depixus but also highlights the company’s dedication to improving health outcomes through innovative research and development. The recognition from peers in the industry serves to validate Depixus’ mission and the hard work of its dedicated team. This accolade has also been prominently featured in various press releases and media coverage, further elevating Depixus’ profile in the biotechnology space.

4. Future Directions and Impact

Looking ahead, Depixus is poised to continue its trajectory of innovation and leadership in the RNA-targeted drug discovery arena. The recent press coverage, including the latest press release, illustrates the company’s ongoing commitment to pushing the boundaries of what is possible in drug development. By focusing on the intricacies of RNA and its interactions within the body, Depixus aims to unlock new therapeutic avenues that can address unmet medical needs.

Moreover, the recognition received through the Ignite Award and the visibility gained from participating in key events like the RNA Targeted Drug Discovery Summit position Depixus favorably within the industry. These milestones will likely attract further collaborations and investments, fostering an environment ripe for scientific breakthroughs.

Conclusion

In summary, Depixus is making significant strides in the field of RNA-targeted drug discovery, as evidenced by its recent press coverage and accolades. With innovative technologies, strategic participation in industry events, and recognition for its contributions, Depixus is setting the stage for a new era in biotechnology. As the company continues to lead the way in RNA research, stakeholders can expect exciting developments that hold the promise of transforming treatment paradigms and improving patient outcomes.

For more information on how Depixus is advancing RNA-targeted drug discovery and to stay updated with our latest news, feel free to contact us today!

Reposted Blog Post URL: https://petrickzag.bcz.com/2024/10/07/depixus-recent-press-release/

[pharmaphorumuk]

3rd RNA-Targeted Drug Discovery Summit

The 3rd RNA- Targeted Drug Discovery Summit returns as the most comprehensive and definitive event for the RNA targeting small molecule community to not only address key challenges of the field, such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of concept to drive the field forward towards translation into clinical development.

With numerous approaches emerging to demonstrate genuine viability in directly or indirectly targeting RNA with small molecules, join leading biopharmaceutical directors, VPs and C-level executives at the 3rd RNA- Targeted Drug Discovery Summit – your premier industry and translational focused conference dedicated to advancing pioneering RNA biology and drug discovery into a blockbuster RNA targeting small molecule therapeutic approach that improves patient outcomes.

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. This view is now changing given the recent progress and scientific breakthroughs in understanding the fundamental biology and function of RNA, opening the door to RNA targeted small molecule drug discovery.

Why You Should Attend the RNA- Targeted Drug Discovery Summit

Explore how to optimize medicinal chemistry insights & RNA biology to enhance robust translation with The Scripps Research Institute, Anima Biotech & Arrakis Therapeutics

Successfully target RNA via interfering with RNA-protein interactions/ Epitranscriptomics with insights from Storm Therapeutics, Accent Therapeutics & Saverna Therapeutics

Expand your knowledge of RNA structure, function & role in disease with insights from Yale University, H3 Biomedicine & Whitehead Institute for Biomedical Research

Advance identification & validation of viable RNA target sites for therapeutic intervention with insights from PTC Therapeutics & Duke University

Overcome binding, selectivity & drug-like challenges of small molecules targeting RNA with insights from Roche, University of California San Diego & Novartis

The post 3rd RNA-Targeted Drug Discovery Summit appeared first on .

from https://pharmaphorum.com/events/3rd-rna-targeted-drug-discovery-summit/

[asfeedin]

What is Crispr Gene Editing? The Complete WIRED Guide

Before long, DuPont bought the Danish company that Barrangou worked for and began using Crispr to protect all of its yogurt and cheese cultures. Since DuPont owns about 50 percent of the global dairy culture market, that means you’ve probably already eaten Crispr-optimized cheese on your pizza.

3 (Non–Gene Editing) Uses for Crispr

Diagnose Disease

Viruses work by turning your cells into little factories for their DNA. A Crispr-based test could pick out that foreign DNA from just a drop of blood, spit, or urine and tell you in minutes if you’ve got the Zika virus, dengue, or yellow fever circulating in your body.

Spot Rot

Every year, fungi wipe out a third of all crops. Crispr panels tuned to identify the worst offenders could help farmers save their harvests before the blight sets in.

Smartbomb Bugs

Thanks to overuse, the world’s antibiotic arsenal is losing its effectiveness. New Crispr-based drugs that only target bad bugs would leave your microbiome intact and help fight antibiotic resistance.

All the while, gene sequencing costs were plummeting and research scientists around the world were assembling the genomes of bacteria. As they did, they found Crisprs everywhere—more than half of the bacterial kingdom turned out to have them. Oftentimes those sequences were flanked by a set of genes coding for a class of strand-cutting enzymes called endonucleases. Scientists suspected they were involved in this primitive immune system, but how exactly?

The key insight came from a particularly nasty bug—the one that causes strep throat. Its Crispr system made two RNA sequences that attached to a clam-shaped endonuclease called Cas9. Like a genetic GPS, those sequences directed the enzyme to a strand of DNA complementary to the RNA sequences. When it got there, Cas9 changed shape, grabbing the DNA and slicing it in two. The molecular biologists who made this discovery—Jennifer Doudna and Emmanuelle Charpentier—published their work on bacteria in Science in 2012. But not before patenting the technology as a tool for genetic engineering. If you just switch out the RNA guide, you can send Cas9 anywhere—to the gene that causes Huntington’s disease, say, and snip it out. Crispr, they realized, would be a molecular biologist’s warp drive.

Six months later, a molecular biologist at the Broad Institute of MIT and Harvard named Feng Zhang published a paper in Science showing how Crispr-Cas9 could edit human cells too. In fact, with the right genetic guides, you can Crispr pretty much anything. That meant it might be put to work on next-generation medicines that could do things like erase genetic defects and supercharge the body’s natural defenses against cancer. And that meant big money.

Perhaps predictably, a patent battle ensued—one that is still going on today. Crispr’s early pioneers founded three companies with exclusive licenses to exploit Crispr/Cas9 to cure human diseases; one of them began its first human trials in early 2019. Uncertainty over who will ultimately own the technology has done little to slow the appetite for all things Crispr. If anything, it unleashed a flood of interest in developing competing and adjacent tools that promise to further refine and expand Crispr’s already ample potential.

Many of the field’s founding luminaries have also formed, or are currently advising, companies working to lower the cost and labor associated with gene editing, to make it accessible to everyone. But in November 2018, at least some of them got a lesson in what democratization of Crispr really looks like.

On the eve of the Second International Summit on Human Gene Editing, news broke that a Chinese scientist named He Jiankui, who was scheduled to speak at the meeting, had been recruiting couples in an effort to create the first Crispr’d babies. Hours later, He Jiankui himself posted five slickly produced promotional videos to YouTube claiming to have already done so: “Two beautiful little Chinese girls, Lulu and Nana, came crying into the world as healthy as any other babies a few weeks ago.” The only difference was that the twins had been injected with Crispr when they were still embryos, in an effort to eliminate a gene called CCR5 and make them resistant to HIV. In a presentation to the summit a few days later, He provided further evidence of his experiment, which he appears to have conducted largely in secret, and revealed that a second pregnancy was underway. Buried in the pages of his clinical paperwork were notes that indicated He had ordered his Crispr components from US biotech companies, in violation of their “research use only” policies.

These firms joined the scientific community’s chorus of disgust, outrage, and near-unanimous condemnation of He’s work. Jennifer Doudna said she was “horrified,” Feng Zhang called for an immediate moratorium on the implantation of gene-edited embryos, and more than 100 Chinese scientists signed a letter decrying the study as “crazy.” Within days, He had been fired from his university post and all his research activities were suspended. A subsequent investigation by government authorities found that He violated Chinese law. He now faces an uncertain fate as he awaits the possibility of official charges.

In the US, multiple investigations are currently ongoing for American scientists suspected to have been involved in—or at least possessing knowledge of—He’s Crispr baby project. Those include Rice University’s Michael Deem and Stanford’s Steven Quake, who is also copresident of the Chan Zuckerberg Biohub.

And as new revelations keep trickling in, policymakers are scrambling to lay down some ground rules for this new Crispr baby world. In March, China formed a new national ethics committee with broad authority over all high-risk medical biotechnologies. It will be tasked with enforcing the country’s new clinical research guidelines, released in February. The World Health Organization is also assembling a panel to develop global standards for governments to follow. Under current US regulations, the Food and Drug Administration is banned from considering any studies that would start a pregnancy with embryos that have been genetically modified. But that language has to be renewed every year by Congress. Given the implausibility of a global consensus on how to move the technology forward responsibly, the task will likely fall to individual nations. Different cultures may have different ideas about the limits on forever altering the genetic destiny of the human species. But one thing is certain. He’s Crispr babies won’t be the last.

Source link

Tags: Complete, CRISPR, crispr/cas9, Editing, Gene, genetic engineering, Guide, Science, WIRED, Wired Guide

from WordPress https://ift.tt/2S9MImj via IFTTT

[mysticalpeacenut]

How RNA Leaders Are Shaping Drug Discovery

The landscape of drug discovery is present process a profound transformation, pushed by the revolutionary insights and improvements in RNA studies. RNA, as soon as taken into consideration simply a messenger amongst DNA and proteins, is now recognized as a key participant within the regulation of gene expression and a promising aim for therapeutic intervention. RNA leaders scientists, researchers, and groups at the leading edge of RNA era - are shaping the destiny of drug discovery in tremendous methods. This blog explores how the ones leaders are leveraging RNA centered drug discovery and development to revolutionize medicinal drug.

The Rise of RNA in Drug Discovery

The exploration of RNA as a healing intention has won momentum due to its pivotal role in cell techniques and illness mechanisms. Unlike conventional drug desires that concentrate on proteins, RNA-targeted drug discovery gives a unique technique to modulate gene expression, imparting the capability to deal with a substantial variety of illnesses, along with genetic issues, cancers, and viral infections.

RNA leaders have recognized the untapped capacity of RNA molecules, collectively with messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA), in influencing ailment pathways. By focused on RNA, researchers can adjust the manufacturing of sickness-inflicting proteins or restore the expression of useful proteins, starting up new avenues for healing intervention.

Advancements in RNA Targeted Drug Discovery

The journey of RNA centered drug discovery has been marked with the resource of good sized improvements in era and information. Scientists have developed revolutionary strategies to design RNA-centered therapeutics which is probably unique, powerful, and stable. These advancements were driven by RNA leaders who are pioneering research in this exciting problem.

RNA Interference (RNAi): RNAi is a groundbreaking era that permits for the selective silencing of unique genes via targeting their mRNA. This approach has paved the way for the improvement of siRNA-based restoration tactics that may exactly goal sickness-inflicting genes and halt their expression.

Antisense Oligonucleotides (ASOs): ASOs are short, synthetic RNA or DNA molecules that bind to complementary mRNA sequences, preventing the production of dangerous proteins. This generation has proven promise in treating genetic problems and illnesses caused by aberrant gene expression.

MRNA Therapeutics: mRNA therapeutics contain turning in artificial mRNA into cells to provide recuperation proteins. This approach has gained prominence with the development of mRNA-primarily based absolutely vaccines, that have established effective in preventing infectious illnesses like COVID-19.

The Role of RNA Leaders

RNA leaders are at the leading edge of driving innovation and improvement in RNA-targeted drug discovery and development. These visionary scientists and groups are pushing the bounds of what is viable and remodeling the panorama of medicine.

Leading RNA-targeted organizations are making an funding in contemporary-day studies and improvement to carry RNA-based treatment options to the leading edge of healthcare. They are collaborating with academic establishments, biotechnology companies, and pharmaceutical groups to boost up the interpretation of RNA discoveries into feasible therapeutics.

Moreover, RNA leaders are actively worried in organizing and taking element in key occasions such as the RNA Targeted Drug Discovery Summit. These summits offer a platform for specialists to percentage insights, communicate disturbing conditions, and find out opportunities in the area of RNA-centered healing processes. By fostering collaboration and understanding alternate, those sports play a critical position in advancing RNA studies and accelerating drug improvement.

RNA Targeted Drug Development: Impact and Potential

The effect of RNA-focused drug improvement on healthcare is profound. RNA-based therapies have the ability to deal with unmet clinical desires and provide answers for diseases that have been formerly considered untreatable. The versatility of RNA technology allows for the development of remedies which might be tailored to specific affected individual populations, paving the manner for personalised medicinal drug.

RNA-focused treatment options provide several benefits, which include excessive specificity, fast improvement timelines, and the potential to aim a wide kind of ailments. As RNA leaders maintain to broaden the sector, the capability for discovering new treatments and improving affected man or woman results is massive.

Looking Ahead

The future of drug discovery is being shaped by way of manner of the innovative efforts of RNA leaders. As research in RNA biology and therapeutics keeps to evolve, we can count on to see more and more RNA-based totally remedy options engaging in clinical trials and, ultimately, the market. The persisted collaboration amongst academia, enterprise, and regulatory bodies might be important in ensuring the successful translation of RNA discoveries into secure and effective remedies.

Conclusion

RNA leaders are spearheading a trendy technology of drug discovery, pushed through the promise of RNA-focused remedies. Their pioneering efforts in RNA centered drug discovery and development are transforming the landscape of drugs and offering choice for sufferers global. As we appearance to the destiny, the capability of RNA-based absolutely therapeutics to deal with complex illnesses and improve healthcare outcomes is clearly interesting.

To examine greater approximately how RNA-centered generation are shaping the future of medicine, go to Depixus. Explore how our modern solutions are advancing RNA research and using development in drug discovery.

Reposted Blog Post URL: https://petrickzagblogger.wordpress.com/2024/08/09/rna-leaders-are-shaping-drug-discovery/

[mysticalpeacenut]

Depixus in the News: Breakthroughs in Therapy

In a year marked by means of fast advancements and step forward discoveries, Depixus has made enormous waves within the clinical community and past. The organization's progressive method to RNA-focused drug discovery and its modern era have captured substantial media interest. Here’s a have a look at the pinnacle media coverage of Depixus this yr, highlighting the important thing moments and developments that have shaped the organization’s narrative.

Major Announcements and Press Releases

One of the standout moments for Depixus this 12 months changed into the release of several key press announcements. These press releases have played a crucial role in maintaining stakeholders and the public knowledgeable approximately the enterprise's state-of-the-art achievements and milestones. Notably, the ultra-modern press launch unveiled the release of Depixus Magna, a present day generation designed to enhance RNA-targeted drug discovery. This announcement received widespread media coverage, highlighting the capability of Magna generation to revolutionize the sphere and improve therapeutic results.

Another sizable press release targeted on Depixus’s collaboration with main pharmaceutical corporations to increase new RNA-based cures. This partnership underscores Depixus's dedication to accelerating drug discovery and addressing unmet clinical needs. The media insurance of this collaboration emphasised how Depixus is leveraging its know-how in RNA-focused technologies to pressure innovation and supply impactful solutions.

Depixus in the News

Depixus has always been featured in distinguished information shops, reflecting the developing interest in its groundbreaking paintings. Articles and reviews on Depixus in the news have highlighted the enterprise’s role in advancing the technology of RNA-centered drug discovery and its contributions to customized medicinal drug.

For example, main biotech and pharmaceutical news platforms have covered Depixus’s involvement in the RNA Targeted Drug Discovery Summit. This summit brought collectively industry leaders and researchers to speak about the brand new improvements in RNA-focused treatment options. Depixus’s shows and participation in panel discussions had been broadly covered, showcasing the organisation’s management in the subject and its dedication to advancing research and improvement.

Coverage of Key Conferences and Summits

Depixus’s presence at key conferences and summits has also garnered large media interest. The RNA Targeted Drug Discovery Summit, in particular, changed into a spotlight of the 12 months. Depixus’s modern displays and discussions on RNA-focused treatment options have been prominently featured inside the media, reflecting the agency's pivotal role in shaping the destiny of drug discovery.

Coverage of these events emphasised the effect of Depixus’s Magna generation and its capacity to deal with crucial demanding situations in drug discovery. Media reports highlighted how Depixus’s contributions are using development within the field, imparting precious insights into the development of recent healing procedures and the destiny of customized medicinal drug.

Impactful Interviews and Expert Opinions

In addition to press releases and convention insurance, Depixus has been featured in a chain of interviews and expert opinion portions. These interviews with Depixus’s management and key scientists have provided in-depth insights into the employer's vision, generation, and strategic desires. Media stores have praised Depixus for its progressive method and its potential to convert the panorama of RNA-targeted drug discovery.

These interviews have not handiest showcased the enterprise’s technical understanding however additionally highlighted the broader implications of its work for the clinical and medical groups. The media’s consciousness on Depixus’s concept leadership and professional evaluations has reinforced the agency's popularity as a main innovator within the field.

Looking Ahead

As Depixus maintains to make strides in RNA-focused drug discovery, the media coverage is predicted to stay strong. The company's ongoing research, technological advancements, and strategic collaborations will likely maintain to seize the attention of both industry specialists and the general public.

The future of Depixus is bright, with many interesting traits at the horizon. As the company builds on its successes and keeps to push the limits of technological know-how and era, it will surely remain a focal point in the media and scientific discourse.

Conclusion

This year has been a amazing one for Depixus, with enormous media insurance highlighting its achievements, improvements, and contributions to RNA-targeted drug discovery. From groundbreaking press releases and convention insurance to impactful interviews and expert critiques, Depixus has firmly installed itself as a pacesetter within the field.

To stay up to date on the today's traits and breakthroughs from Depixus, go to Depixus. Discover how our pioneering technologies are shaping the future of drugs and join us on our adventure to revolutionize drug discovery.

Reposted Blog Post URL: https://petrickzagblogger.wordpress.com/2024/08/05/depixus-in-the-news-breakthroughs/

[pharmaphorumuk]

2nd RNA Targeted Drug Discovery Summit

At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential.

For the 2nd year, network with the KOLs and RNA pioneers, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA.

Download the Full Event Guide to view the comprehensive 3 day agenda and expert speaker faculty.

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, join the 2nd RNA- Targeted Drug Discovery Summit – the only industry and translational focused conference dedicated to advancing pioneering RNA targeted small molecule therapeutics.

Expand your knowledge of RNA structure, function & role in disease with insights from Beth Israel Deaconess Medical Center, University of North Carolina & Northwestern University

Successfully target RNA via interfering with RNA-protein interactions/ epitranscriptomics with insights from Storm Therapeutics, Accent Therapeutics & Gotham Therapeutics

Advance identification & validation of viable RNA target sites for therapeutic intervention with insights from Bristol-Myers Squibb, PTC Therapeutics & Merck

Overcome binding, selectivity & drug-like challenges of small molecules targeting RNA with insights from Pfizer, Novartis & Weill Cornell Medicine

Join the momentum to reverse the undruggable nature of RNA and seize the enormous therapeutic potential with R&D and strategic insights from Anima Biotech, Arrakis Therapeutics & Eli Lilly

Download the Full Event Guide for the full agenda and speaker line-up.

The post 2nd RNA Targeted Drug Discovery Summit appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/